Funabashi, Japan

Yasutaka Takada




Average Co-Inventor Count = 4.3

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Chiba, JP (2002 - 2008)
  • Funabashi, JP (2010 - 2017)

Company Filing History:


Years Active: 2002-2017

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Yasutaka Takada: Innovator in Pharmaceutical Chemistry

Introduction

Yasutaka Takada is a prominent inventor based in Funabashi, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 6 patents. His work focuses on developing methods for producing optically active compounds that are crucial for drug development.

Latest Patents

One of Takada's latest patents is a method for producing optically active 5-hydroxy-3-ketoester. This invention aims to provide a high-yield and high-stereoselectivity method for creating this compound, which serves as an important intermediate in pharmaceuticals. Another notable patent involves the crystal form of a tricyclic benzopyran compound, specifically (3R,4S)-7-hydroxymethyl-2,2,9-trimethyl-4-(phenethylamino)-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol. This patent outlines production methods that include crystallization from various solvents, enhancing the compound's utility as a drug.

Career Highlights

Yasutaka Takada is currently employed at Nissan Chemical Industries Limited, where he continues to innovate in the field of chemical production. His expertise in asymmetric reactions and crystallization techniques has positioned him as a valuable asset in pharmaceutical research and development.

Collaborations

Throughout his career, Takada has collaborated with notable colleagues such as Hiroo Matsumoto and Yuji Yoshimura. These partnerships have fostered a collaborative environment that enhances the innovation process within the company.

Conclusion

Yasutaka Takada's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key inventor in the industry. His work continues to impact the development of essential pharmaceutical compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…